Research Evidence / Overview of Studies for Mycoderm-C
This overview describes the research landscape for topical Clotrimazole, the active ingredient in Mycoderm-C, based on official regulatory reviews and published scientific literature. The focus is on the types of studies conducted, the outcomes measured, and the limitations noted in the evidence.
Evidence for Use in Dermatophytoses (Ringworm, Athlete's Foot, and Jock Itch)
The research for fungal skin infections was evaluated in studies that included Randomized Controlled Trials (RCTs). These short-term RCTs, further analyzed in Systematic Reviews and Meta-analyses, were conducted during periods of increased symptom activity. Studies monitored outcomes such as mycological cure (clearance of the fungus) and clinical cure (resolution of visible signs and patient-reported discomfort). The trials typically observed responses over defined time intervals and included adults, adolescents, and children over the age of two who had confirmed diagnoses.
Findings describe patterns observed regarding mycological and clinical clearance measurements. Research highlights changes measured during the study period, often comparing Clotrimazole to a substance without medicine (placebo) or to other topical antifungals. This evidence base is categorized as having a High level of consistency across the primary outcomes examined.
Despite the body of available evidence, certainty remains low regarding outcomes after the end of the treatment period. Follow-up durations were limited in many studies, meaning long-term effects are not fully established concerning the infection returning. Evidence quality varies across studies when drawing broad comparisons.
Evidence for Use in Cutaneous Candidiasis (Skin Yeast Infections)
Topical Clotrimazole was studied for cutaneous candidiasis primarily through Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. The studies explored outcomes linked to inflammatory or irritative states, focusing on achieving mycological cure and clinical cure rate. Research examined populations spanning a wide age range, including infants, children, adolescents, adults, and older adults.
The aggregated data from these studies showed consistent patterns in measurements of mycological and clinical clearance across the various age groups observed. Studies reported short-term clinical cure findings that were observed in relation to measurements documented for other medications in the azole class. The evidence supporting these core short-term outcomes is labeled as having a High level of consistency.
However, there is limited information for long-term outcomes, as existing studies provide limited insight into the long-term durability of clearance following the conclusion of treatment. Comparative evidence is lacking for different topical forms of the medication.
Evidence for Use in Pityriasis Versicolor
The research available for Pityriasis Versicolor includes Comparative Studies and Historical Clinical Data. This research examined temporary physiological imbalance, specifically looking at outcomes related to mycological cure and clinical improvement or clearance of discolored lesions. This evidence was observed in settings with varying symptom burdens and primarily included adults. The existing data for this indication are categorized as having a Moderate level of consistency.
Research highlights that fewer recent, large-scale RCTs have been conducted specifically for this condition compared to the dermatophytoses indication. The available data are still emerging concerning the risk of recurrence, as follow-up durations were limited and there is limited information for long-term outcomes.
Long-Term Studies and Durability of Response
Research was studied for the durability of clearance and the incidence of relapse following the initial treatment phase. However, the regulatory evidence base primarily consists of trials exploring short-term changes over short-term follow-up durations (typically 2 to 4 weeks).
Evidence suggests that long-term effects are not fully established because the duration of observation was short in many pivotal studies. Research provides context but not individual predictions regarding whether the infection will return. Findings describe group patterns related to relapse monitoring in some trials, but comprehensive data extending months or years beyond the end of treatment are generally considered to be insufficient.
Evidence in Specific Patient Populations
Topical Clotrimazole was evaluated in studies that included different age groups. The evidence base for dermatophytoses and cutaneous candidiasis includes studies that evaluated children ge 2 years and older adults, helping to contextualize how patients reported their experience across these age ranges.
However, data for certain groups remain insufficient. Detailed research examining outcomes for individuals with specific complex comorbidities or varying levels of immune function is limited. This means results apply only to the populations studied, and subgroup findings are uncertain when moving beyond the general patient populations included in the core clinical trials.
Research Gaps and Areas of Uncertainty
The research landscape highlights several areas where further investigation is needed. Long-term effects are not fully established, as the duration of follow-up in most clinical trials was limited to immediate post-treatment periods. This limits insight into the long-term patterns of recurrence.
Furthermore, evidence quality varies across studies due to the differences in how trials were designed, which can make consistent comparison of findings challenging. Comparative evidence is lacking for some formulations and specific subgroups. Research contributes to understanding short-term changes, but the evidence highlights what is known—and what is still uncertain—about outcomes over many months or years.
